Ambergen Technology

Ambergen is developing advanced technology for the discovery and detection of molecular profiles characteristic of specific human diseases.

Such profiles or signatures enable early detection, diagnosis and prognosis of diseases allowing physicians to more accurately make optimal therapeutic decisions tailored to individual patients.

At the core of Ambergen products is unique technology for biomolcular analysis covered by over 35 U.S. patents including:

LIVE-PRO

Ambergen is developing cell-free expressed proteome bead-display technologies, or Bead Sorted Libraries of in vitro Expressed Proteins (BS-LIVE-PRO) which are produced from Bead Sorted Libraries of in vitro Expressible DNA (BS-LIVE-DNA). BS-LIVE-DNA are produced in a single solid-phase PCR reaction and then converted to BS-LIVE-PRO on-demand, in a few hours, using multiplex cell-free protein expression.

PC-Linkers

Compounds and Methods developed by Ambergen to manipulate biomolecules with light. One example is PC-Biotin™ a unique form of biotin which allows biomolecules to be captured and then released with light. PC-biotin is one example of a line of Ambergen photocleavable (PC) products that facilitate the detection and discovery of biomarkers including PC-phosphoramidites, PC-fluoro-nucleotides and PC-ICAT compounds (PC-phosphoramidites are currently marketed by Glen Research, Sterling, VA).

T²-ELISA

Ambergen has integrated cell-free antigen production into a patented epitope tag based ELISA platform.

T²-ELISA can be used both in screening mode, for instance to validate the results of biomarker discovery assays, or as the final commercial diagnostic assay itself.

TRAMPE

Ambergen is a leader in the area of tRNA mediated Protein Engineering (TRAMPE). One example is FluoroTags™ fluorescently labeled tRNAs which elminiate the need for radioactivity in research and diagnostic tests involving cell-free protein synthesis (currently marketed by Promeda Corporation as Fluorotect™). FluoroTags are one example of a line of products developed by Ambergen to accelerate the study of the human proteome through analysis of libraries of in vitro expressed proteins (LIVE-PRO™).